Key Takeaways
- Biomap claims to surpass AlphaFold in drug discovery commercialization efforts.
- The company aims to launch its first drug in Hong Kong within 12 to 24 months.
- Biomap’s revenue is projected to double this year amidst geopolitical challenges.
Biomap’s AI Advancements in Drug Discovery
Biomap, a biotechnology start-up co-founded by Baidu’s Robin Li Yanhong and supported by the Hong Kong government, claims it has outpaced Alphabet’s AlphaFold in the commercialization of AI models for drug discovery. CEO Wei Liu noted a “reverse” in the technological gap, stating, “In terms of commercialization and projects developed based on our models, I think we are ahead of AlphaFold.” Although he acknowledged AlphaFold’s superior academic influence, Liu emphasized Biomap’s progress.
AlphaFold, developed by DeepMind, excels in predicting molecular structures and interactions crucial for developing new therapies. Biomap is emerging among several Chinese firms, including ByteDance, which has created its own molecular prediction model named Protenix.
Last year, Biomap’s xTrimo models indicated higher accuracy than AlphaFold in analyzing interactions between various antibodies. Established in 2020, Biomap secured funding from the Hong Kong Investment Corporation (HKIC) to enhance the local biotech ecosystem through the BioMap InnoHub accelerator. This initiative has incubated over ten projects and aims to expand to 50 projects and 20 companies by 2030.
Recently, Biomap announced the co-founding of BioGend Science, a new company focused on drug commercialization, alongside Legend Capital, a subsidiary of Lenovo’s parent company. Liu mentioned that BioGend aims to enter clinical trials for its first drug in the next 12 to 24 months, making use of Biomap’s AI platform and local research resources.
Despite facing geopolitical risks, Biomap anticipates its revenue to double this year, having attracted nearly 1,000 clients and several multinational pharmaceutical partnerships within the past year. Liu acknowledged that while geopolitical tensions pose challenges, they also strengthen Biomap’s commitment to advancing life sciences through collaboration.
To support its growth, Biomap has diversified its computing infrastructure and made its models compatible with AI chips from various Chinese companies, including Huawei and Baidu. Liu confirmed that Biomap is progressing with initial public offering plans, prioritizing a listing in Hong Kong but did not disclose specific timelines.
Overall, Biomap is positioning itself as a significant player in the biotechnology landscape, pushing forward with its innovative AI-driven solutions and laying the groundwork for future expansion.
The content above is a summary. For more details, see the source article.